TABLE 1

Patient characteristics by empiric treatmenta

CharacteristicValues for patients treated with:P value for carbapenem vs cefepimeValues for patients treated with piperacillin-tazobactam (n = 21)P value for piperacillin-tazobactam vs a carbapenem
Carbapenem (n = 42)Cefepime (n = 40)
Median (IQR) age (yr)52 (31–61)54 (38–61)0.4254 (35–59)0.77
No. (%) of male patients25 (59)26 (65)0.6514 (67)0.78
Median (IQR) Pitt bacteremia score3 (1–3)2 (1–3)0.031 (1–2)0.01
Median (IQR) CLCR (ml/min)115 (76–165)115 (76–171)0.22120 (100–150)0.47
No. (%) of patients with:
    Leukemia diagnosis39 (93)26 (65)<0.0121 (100)0.29
    Prior HCT18 (43)23 (58)0.263 (14)0.27
Median (IQR) ANC (no. of cells/mm3)0 (0–0)0 (0–0)0.090 (0–20)0.38
No. (%) of patients in ICU15 (36)6 (15)0.044 (19)0.25
No. (%) of patients receiving chemotherapy36 (86)30 (75)0.2719 (90)0.71
No. (%) of patients receiving combination aminoglycoside24 (57)13 (33)0.037 (33)0.11
No. (%) of patients with the following duration of neutropeniab of:0.270.14
    ≥7 days22 (52)15 (38)10 (48)
    <7 days17 (40)24 (60)6 (29)
No. (%) of nonneutropenic patients2 (5)1 (3)5 (24)
No. (%) of patients with the following source of bacteremia:0.430.14
    Central line7 (17)9 (23)0 (0)
    Respiratory6 (14)1 (3)1 (5)
    Abdominalc16 (38)19 (48)9 (43)
    Urinary4 (10)2 (5)2 (10)
    Skin/soft tissue2 (5)3 (8)4 (19)
    Unknown7 (17)6 (15)5 (24)
  • a CLCR, Cockcroft-Gault creatinine clearance; HCT, hematopoietic stem cell transplant; ANC, absolute neutrophil count; ICU, intensive care unit.

  • b ANC < 500 cells/mm3.

  • c Includes presumed translocation.